BioSpace News Archive

Invacare Corporation (NYSE: IVC) (“Invacare” or the “company”) today reported results for the quarter ended March 31, 2019.

Hill-Rom Holdings, Inc. (NYSE: HRC), announced today that it will present at the UBS 2019 Global Healthcare Conference on Monday, May 20, 2019, in New York.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ:NBRV).

The U.S. Food and Drug Administration today approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.

Magenta Therapeutics, Inc. announced the closing of its previously announced public offering of 4,887,500 shares of its common stock, including 637,500 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $13.25 per share.

Cash Balance of $205 Million at March 31, After Purchases of $24 Million of Term Loans

Aflac Incorporated announced that Max K. Brodén has been named senior vice president; deputy chief financial officer and treasurer of Aflac Incorporated, reporting to Aflac Incorporated Executive Vice President and Chief Financial Officer Frederick J. Crawford.

CannTrust Holdings Inc. announced the closing of its previously-announced underwritten public offering of 36,363,636 common shares at a price to the public of US$5.50 per share.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the first quarter of 2019, meeting its outlook for net sales growth at constant exchange rates, or CER, and exceeding the outlook for adjusted earnings per share at CER while driving global expansion of its Sample to Insight portfolio of molecular testing solutions.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock